Brief introduction of Beijing Novartis pharmaceutical co., ltd.

1996 following the global merger of Ciba Cargill and Sandoz, its pharmaceutical business in China was merged, and Novartis' first company in China, Beijing Novartis Pharmaceutical Co., Ltd., was established.

In the past ten years, Beijing Novartis has made remarkable achievements, covering more than 260 cities across the country, with a compound growth rate of over 20%. In 2006, the company's sales reached1800 million yuan. In 2008, the total sales of Novartis in China exceeded RMB 3.3 billion. At the same time, Novartis China also actively promoted social welfare undertakings and won several corporate social responsibility awards.

Novartis Pharmaceuticals has set up General Drugs Division, Anti-infective Drugs Division, Transplantation and Central Nervous Drugs Division, Ophthalmology Drugs Division and Oncology Drugs Division in China, and implemented regional management, thus establishing a highly competitive product portfolio. The company has more than 30 world-class high-tech patented products in cardiovascular, endocrine, anti-infection, tumor, transplantation immunity, rheumatic pain, bone metabolism, ophthalmology, central nervous system, dermatology, gastroenterology and other fields. The market share of related products ranks first in the field of angiotensin converting enzyme inhibitors, second in the field of angiotensin antagonists and first in the field of transplantation.

In 2006, Beijing Novartis Pharmaceutical successfully completed the handover of senior leaders. On June 5438+1 October1day, 2006, Mr. Liu, the former CEO and president of Beijing Novartis Pharmaceutical Co., Ltd., was appointed as the chairman of Beijing Novartis Pharmaceutical Co., Ltd. and the general manager of OTC Pharmaceutical Division in China District. Mr. Deng Jianmin, former chief operating officer of Beijing Novartis Pharmaceutical Co., Ltd., was promoted to CEO and President of Beijing Novartis Pharmaceutical Co., Ltd.

In 2007, the company listed telbivudine, an anti-hepatitis B virus drug, in China. Clinical trials show that subivor is obviously superior to lamivudine and adefovir, which can effectively inhibit virus replication, with high seroconversion rate of E antigen and excellent safety and tolerance. Therefore, Subivor has become a first-line drug for the treatment of hepatitis B. In the next few years, the company will launch a number of new products in China to meet the needs of China patients and serve the health of China people.

Beijing Novartis Changping Factory is being expanded with an investment of 24 million US dollars, which will increase the production capacity by 200% after completion. The new warehouse was officially put into use on June 26th, 2007. The new production and packaging process will run in the second quarter of 2007, and the original factory upgrade will be completed in the first quarter of 2008.